Craif Starts Joint Research with National Cancer Center Hospital East Conducts multicenter joint research to examine the usefulness of urinary microRNA analysis in diagnosis and radiotherapy for head and neck squamous cell carcinoma and rectal cancer

1. Multicenter observational research on diagnosis and radiation therapy of urinary microRNA analysis in head and neck squamous epithelial cancer Radiation therapy for head and neck cancer can preserve function and structure unlike surgical surgery. On the other hand, detection of early recurrence after treatment is important when considering the application of early salvage surgery. Although it is technically possible to perform a local biopsy to directly confirm the response after radiation therapy, it is problematic that radiation therapy will lead to prolongation of acute adverse events due to its large invasiveness. I've been. Urinary microRNA (hereinafter referred to as miRNA) measurement is non-invasive, and it is being shown that various cancers can be diagnosed and recurrence can be predicted by examining the profile. Through this study, we will analyze the correlation between the profile of urinary miRNA and the response rate and prognosis of radiation therapy to examine whether the response and prognosis to diagnosis and treatment can be predicted. 2. Multicenter joint research on the usefulness of urinary microRNA analysis in preoperative chemoradiotherapy for rectal cancer In recent years, radiation therapy has been widely used in cancer treatment. The greatest usefulness of radiation therapy is that it can be curatively treated while preserving the organs, and preoperative chemoradiotherapy is one of the standard treatments for locally advanced rectal cancer. Although it is positioned as preoperative treatment on the premise of surgery, it is said that a complete pathological response can be obtained at around 20% even with preoperative chemoradiation therapy. Options to avoid and follow up are also being considered. However, there are quite a few cases of recurrence during follow-up, and the development of biomarkers that can predict the disease state is desired. In this study, we will examine whether responsiveness to treatment and recurrence can be predicted by analyzing urinary miRNA before and after preoperative radiation therapy for rectal cancer. ■ About Craif Craif is a venture company from Nagoya University founded in May 2018. We are working to solve various problems in current cancer treatment by comprehensively capturing miRNA from urine using the material power that Japan is proud of and applying it to medical treatment in combination with AI (artificial intelligence). .. By using the zinc oxide nanowire device developed by our company, miRNA can be comprehensively captured more easily and efficiently than the conventional method. By analyzing miRNAs that control gene expression, we can deepen our understanding of many diseases including cancer. By applying this technology, we are working on the development of tests that detect cancer from urine with high accuracy at an early stage and tests that enable the selection of the optimal treatment for each individual. We provide this technology as a next-generation biomarker analysis service, and through collaboration with all companies and academia, mainly in the medical and healthcare fields, our vision is "realization of a society where people can fulfill their natural lives." I will promote. For more information, please visit https://craif.com/. ■ Company Profile Company Name: Craif Co., Ltd. Headquarters Location: 3-38-14 Hongo, Bunkyo-ku, Tokyo NEOS Building 3F Representative: CEO Ryuichi Ono Established: May 2018 URL: https://craif.com/ * Below , This is special information only for media personnel. Please refrain from disclosing information on personal SNS etc.

This press release contains information for the media.

If you register as a media user, you can view various special information such as contact information of the person in charge of the company and information on events and press conferences. * Contents vary depending on the press release.

1. Press Release>
2. Craif Co., Ltd.>
3. Craif Starts Joint Research with National Cancer Center Hospital East Conducts multicenter joint research to examine the usefulness of urinary microRNA analysis in diagnosis and radiotherapy for head and neck squamous cell carcinoma and rectal cancer